. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: Addiction. 2017 Feb 8;112(6):1036–1044. doi: 10.1111/add.13753

Table 3.

Secondary Outcomes.

	TAU		XR-NTX
	Baseline	16 weeks	Baseline	16 weeks
Opioid Use
Mean days of opioid use in past 30 days¹	17.3 (SD=13.14) n=12	4.1 (SD=5.43) n=11	20.3(SD=12.29) n=12	7.7 (SD=11.32) n=11
UDS positive for opioids¹	9 (75.0%) n=12	7 (58.3%) n=12	9 (75.0%) n=12	4 (40.0%) n=12
Alcohol Use
Mean days of alcohol use in past 30 days²	15.6 (SD=9.95) n=14	5.7 (SD=8.40) n=12	12.5 (SD=11.02) n=13	2.8 (SD=3.05) n=12
Urine ethylglucuronide positive, n (%)²	7 (50.0%) n=14	4 (30.8%) n=14	6 (54.5%) n=13	3 (25.0%) n=13
HIV Outcomes
Prescribed ART³	25 (96.2%) n=26	26 (100%) n=26	23 (92.0%) n=25	24 (96.0%) n=25
HIV Viral Suppression³	21 (80.8%) n=26	20 (87.0%) n=23	20 (80.0%) n=25	17 (81.0%) n=21

Among participants with opioid use disorder retained at 16 weeks

Among participants with alcohol use disorder retained at 16 weeks

Among all participants completing study assessments